1297P A phase II study of pyrotinib combined with apatinib in first-line treatment of advanced non-small cell lung cancer patients with primary HER-2 mutations/amplification - Jiang, W; Yang, Y; Yang, G; Xu, H; Wang, Y (Ann Oncol, 2024)